Radioimmunometric Assay to measure Anti-SARS-COV2 Antibodies in Serum
Unaltered image by Marco Verch
Opportunity
Available for Licensing and Collaboration
IP Status
US Utility Patent Pending (Not Yet Published)
Inventors
Torrance “Terry” M Nett
Eric Weber
At A Glance
Researchers at Colorado State University have developed a radioimmunometric assay (RIA) to detect and quantitate antibodies against SARS-COV2 in serum.
For more details please contact our office.
Technology Highlights
- Assay is an offshoot of the classic double antibody radioimmunoassay
- Directly measure the amount of radiolabeled pathogen-specific antigen that is bound in immune complexes following the addition of a serum sample
- Not only can detect the presence of pathogen-specific antibodies, but can quantitate the concentration in serum
- Developing detection using assay with sputum (to avoid invasive blood draws)
- Assay will be validated under guidance of the FDA (EUA)
- High sensitivity – see Figure 1 below
Figure 1:
Five samples were analyzed at a dilution of 1:10. The % binding vs the log PRNT90 (antibody titer) were graphed, showing a correlation between the PRNT90 and % binding of r = 0.98
Benefits
- More sensitive than other types of assays
- Can quantify antibody concentration
- Cost is significantly less than ELISA assays
Applications
- Clinical Labs with RIA capabilities
- Pharma and University Research
Last updated: June 2020
Add keywords or various names of inventors here (text is hidden)